We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00223301
First Posted: September 22, 2005
Last Update Posted: April 22, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Roche Pharma AG
Biogen
Information provided by (Responsible Party):
Elliot Frohman, University of Texas Southwestern Medical Center
  Purpose
  1. To determine the safety and tolerability of oral Cellcept when used in combination with weekly intramuscular Avonex in early MS.
  2. To document changes in exacerbation frequency,
  3. To document the incidence of mild, moderate, and severe exacerbations in the treated groups (categorical analysis),
  4. To document changes in the level of sustained disability as measured by the expanded disability status score (EDSS) and ambulation index (AI),
  5. To document changes in quality of life measures,
  6. To assess fatigue with the validated fatigue assessment inventory,
  7. Neuroimmunological studies:At baseline, 6 and 12 months after treatment

Condition Intervention Phase
Multiple Sclerosis Drug: Mycophenolate Mofetil (cellcept) Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Elliot Frohman, University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • The primary objective of this safety/mechanistic study is to determine the safety and tolerability of oral Cellcept when used in combination with weekly intramuscular Avonex in early MS. Early MS for this study is defined at a definite diagnosis of less

Secondary Outcome Measures:
  • To document changes in exacerbation frequency
  • To document the incidence of mild, moderate, and severe exacerbations in the treated groups.
  • To document changes in the level of sustained disability as measured by the expanded disability status score (EDSS) and ambulation index (AI) as assessed by the Kaplan-Meier methodology.
  • To document changes in quality of life measures (MSQOL-54, SF-36, and Beck's Depression Index).
  • To assess fatigue with the validated fatigue assessment inventory
  • Neuroimmunological studies:At baseline, 6 and 12 months after treatment.
  • Pharmacodynamics.
  • Genetic Studies.

Estimated Enrollment: 24
Study Start Date: July 2004
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Design: Uni-center, double-blind, randomized, placebo-controlled study of Avonex + placebo vs Avonex + Cellcept

Rationale: A number of immunopathogenic mechanisms have been hypothesized to figure prominently in the processes that culminate in the characteristic plaque lesion. These include the role of cytokines, chemokines, excitatory amino acids, free radicals, superoxides, and nitric oxide synthetase products. Recognizing that the disease process in MS involves a cascade of biological events, sets the stage for strategically targeting specific immunopathogenetic steps through rational combination therapy regimens. We now propose a combination clinical trial utilizing Avonex and mycophenolate mofetil (MMF), a novel agent with a broad spectrum of anti- inflammatory mechanisms.

  • Study population: MS patients who have been diagnosed with clinically definite, laboratory supported definite, or monosymptomatic MS meeting CHAMPS criteria ref , of either sex, who are between the ages of 21 and 50 inclusive.
  • Treatment Groups: 12 patients in each group, ALL patients on Intramuscular Avonex. Cellcept/Placebo will be started at 250mg bid for one week and then escalated by 250mg bid until a target dose of 1000mg bid is achieved and Avonex 30 mcg IM q week

Patients also see an examining physician every three months, have brain MRI scans done every other month and donate WBCs through a procedure called leukapheresis (done every six months).

  • Efficacy Parameters/Evaluations: EDSS, PSAT, MSFC and MRI, relapse rate and safety measures
  • Safety Parameters/Evaluations: Safety will be assessed by virtue of changes in T2/FLAIR lesions (number and volume) and in gadolinium enhancements (measured at 6 and 12 months after treatment initiation) compared to baseline measurements derived from one pretreatment run- in scan. In addition, a variety of clinical assessments will be performed for the period of 12 months of treatment. We will enroll 12 patients in each group (24 total)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Between the ages of 21-45 inclusive
  2. Clinically definite, laboratory supported definite relapsing MS of less than or equal to two years in duration or monosymptomatic MS meeting CHAMPS criteria ref .
  3. At least one exacerbation in the preceding two years
  4. Written informed consent.

Exclusion Criteria:

  1. Primary progressive, secondary progressive or progressive relapsing MS.
  2. Corticosteroids during the 60 days prior to study entry.
  3. Treatment with plasma exchange within 90 days of preenrollment.
  4. No prior exposure to total lymphoid irradiation.
  5. No prior use of interferons, monoclonal antibodies, glatiramer acetate, methotrexate or other immunomodulatory drugs
  6. A clinical relapse within 60 days prior to enrollment.
  7. Pregnant/breastfeeding.
  8. Patients with major medical illnesses.
  9. Cognitive impairment interfering with ability to comply with the protocol.
  10. Patients who need to remain on any contraindicated medication.
  11. Diabetic
  12. Inability to undergo MRI scan
  13. On intravenous immunoglobulin protocol
  14. HIV+ or RPR+
  15. Females of childbearing age who have not undergone a sterilization procedure must be willing to practice effective birth control.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00223301


Locations
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390-8806
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Roche Pharma AG
Biogen
Investigators
Principal Investigator: Elliot Frohman, MD/PhD UT Southwestern Medical Center
  More Information

Responsible Party: Elliot Frohman, Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT00223301     History of Changes
Other Study ID Numbers: 1103-716
First Submitted: September 19, 2005
First Posted: September 22, 2005
Last Update Posted: April 22, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action